Risk | Moderately High |
---|---|
Min SIP Amount | Not Supported |
Expense Ratio | 0.00% |
NAV | ₹11.04 (21 Jan 2021) |
---|---|
Fund Started | 27 Mar 2018 |
Fund Size | ₹277 Cr |
Name | Sector | Instrument | % Assets |
---|---|---|---|
Mahindra & Mahindra Ltd. | Automobile | Equity | 6.1% |
Escorts Ltd. | Automobile | Equity | 6.0% |
ITC Ltd. | FMCG | Equity | 5.9% |
Bharti Airtel Ltd. | Communication | Equity | 5.9% |
Colgate-Palmolive (India) Ltd. | FMCG | Equity | 5.2% |
PI Industries Ltd. | Chemicals | Equity | 5.1% |
Chambal Fertilisers & Chemicals Ltd. | Chemicals | Equity | 5.0% |
Mahindra & Mahindra Financial Services Ltd. | Financial | Equity | 5.0% |
Coromandel International Ltd. | Chemicals | Equity | 4.7% |
Rallis India Ltd. | Chemicals | Equity | 4.0% |
UTI Long Term Advantage Fund Series VII Direct Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 27 Mar 2018. Lalit Nambiar is the Current Fund Manager of UTI Long Term Advantage Fund Series VII Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹277 Cr and the Latest NAV as of 21 Jan 2021 is ₹11.04.
The UTI Long Term Advantage Fund Series VII Direct Growth is rated Moderately High risk.
The investment objective of the scheme is to provide medium to long term capital appreciation along with income tax benefit.